Современные возможности местной терапии угревой болезни

1. Cunliffe WJ, Gould DJ. Prevalence of facial acne vulgaris in late adolescence
and in adults. BMJ 1979; 1: 1109–10.
2. Майорова С.А., Шаповалов В.С., Ахтямов С.Н. Угревая болезнь в
практике врача-дерматокосметолога. М.: Фирма Клавель, 2005;
6–85.
3. Picardi A, Abeni D, Melchi CF et al. Psychiatric morbidity in dermatological
outpatients: an issue to be recognized. Br J Dermatol 2000; 143:
983–91.
4. Mallon E, Newton JN, Klassen A et al. The quality of life in acne: a
comparison with general medical conditions using generic questionnaires.
Br J Dermatol 1999; 140: 672–6.
5. Cunliffe WJ. Acne and unemployment. Br J Dermatol 1986; 115: 386.
6. Gollnick HPM, Zouboulis CC, Akamatsu H et al. Pathogenesis and
pathogenesis-related treatment of acne. J Dermatol 1991; 18: 489–99.
7. Thiboutot D, Knaggs H, Gilliland H et al. Activity of 5-α-reductase and
17-α-hydroxysteroid dehydrogenase in the infraindibulum of subjects
with and without acne vulgaris. Dermatology 1998; 196: 38–42.
8. Thiboutot DM, Knaggs H, Gilliland K et al. Activity of type 1 5-α-
reductase is greater in the follicular infrainfundibulum compared with
the epidermis. Br J Dermatol 1997; 136: 166–71.
9. Fritsch M, Orfanos CE, Zouboulis CC. Sebocytes are the key regulators
of androgen homeostasis in human skin. J Invest Dermatol 2001; 116:
793–800.
10. Cunliffe WJ, Holland DB, Clark SM et al. Comedogenesis: some new
aetiological, clinical and therapeutic strategies. Br J Dermatol 2000;
142: 1084–91.
11. Webster GF, Leyden JJ, Musson RA, Douglas SD. Susceptibility of Propionibacterium
acnes to killing and degradation by human neutrophils
and monocytes in vitro. Infect Immun 1985; 49 (1): 116–21.
12. McGinley KJ, Webster GF, Ruggieri MR, Leyden JJ. Regional variations
in density of cutaneous propionibacteria: correlation of Propionibacterium
acnes with sebum secretion. J Clin Microbiol 1980; 12: 672–5.
13. Cove JH, Holland KT, Cunliffe WJ. An analysis of sebum excretion
rate, bacterial population and the production rate of free fatty acids on
human skin. Br J Dermatol 1980; 103: 383–6.
14. Leeming JP, Holland KT, Cunliffe WJ. The microbial colonization of
inflamed acne vulgaris lesions. Br J Dermatol 1988; 118: 203–8.
15. Jappe U, Ingham E, Henwood J, Holland KT. Propionibacterium
acnes and inflammation in acne; P. acnes has T-cell mitogenic activity.
Br J Dermatol 2002; 146: 202–8.
16. Wolf JE Jr, Kaplan D, Kraus SJ et al. Efficacy and tolerability of combined
topical treatment of acne vulgaris with adapalene and clindamycin:
A multicenter, randomized, investigatorblinded study. J Am
Acad Dermatol 2003; 49: S211–7.
17. Gollnick H, Schramm M. Topical drug treatment in acne. Dermatology
1998; 196: 119–25.
18. Thielitz A, Helmdach M, Ro? pke EM, Gollnick H. Lipid analysis of follicular
casts from cyanoacrylate strips as a new method for studying
therapeutic effects of antiacne agents. Br J Dermatol 2001; 145: 19–27.
19. Verschoore M, Bouclier M, Czernielewski J, Hensby C. Topical
retinoids: their uses in dermatology. Dermatol Clin 1993; 11: 107–15.
20. Hensby C, Cavey D, Bouclier M et al. The in vivo and in vitro antiinflammatory
activity of CD271: a new retinoid-like modulator of cell
differentiation. Agents Actions 1990; 29: 56–8.
21. Thielitz A, Helmdach M, Ro? pke EM, Gollnick H. Lipid analysis of follicular
casts from cyanoacrylate strips as a new method for studying
therapeutic effects of antiacne agents. Br J Dermatol 2001; 145: 19–27.
22. Kligman AM, Fulton JE Jr, Plewig G. Topical vitamin A acid in acne
vulgaris. Arch Dermatol 1969; 99: 469–76.
23. Shalita A, Weiss JS, Chalker DK et al. A comparison of the efficacy and
safety of adapalene gel 0,1% and tretinoin gel 0,025% in the treatment
of acne vulgaris: a multicenter trial. J Am Acad Dermatol 1996; 34:
482–5.
24. Gollnick H, Cunliffe W, Berson D et al. Management of acne: a report
from a Global Alliance to Improve Outcomes in Acne. J Am Acad Dermatol
2003; 49 (1 suppl.): S1–S37.
25. Cunliffe WJ, Meynadier J, Alirezai M et al. Is combined oral and topical
therapy better than oral therapy alone in patients with moderate to
moderately severe acne vulgaris? A comparison of the efficacy and safety
of lymecycline plus adapalene gel 0,1%, versus lymecycline plus gel
vehicle. J Am Acad Dermatol 2003; 49 (suppl. 2): 18–26.
26. Ozolins M, Eady EA, Avery AJ et al. Comparison of five antimicrobial
regimens for treatment of mild to moderate inflammatory facial acne
vulgaris in the community. A randomized controlled trial. Lancet 2004;
364: 2188–95.
27. Thielitz A, Helmdach M, Rцpke E-M, Gollnick H. Lipid analysis of follicular
casts from cyanoacrylate strips as a new method for studying
therapeutic effects of antiacne agents. Br J Dermatol 2001; 145 (1):
19–27.
28. Монахов С.А., Иванов О.Л., Самгин М.А. Антиандрогенная тера-
пия акне у женщин. Рос. журн. кожн. и венерол. бол. 2005; 3:
66–70.
29. Bordat P, Chesnoy S. Mixing glycolic acid with retinaldehyde: RALGA,
a technical achievement. Dermatology 2005; 210 (Suppl. 1): 2–5.
30. Tran C, Kasraee B, Grand D et al. Pharmacology of RALGA, a mixture
of retinaldehyde and glycolic acid. Dermatology 2005; 210 (Suppl. 1):
6–13.
31. Poli F, Ribet V, Lauze C et al. Efficacy and safety of 0,1% retinaldehyde/
6% glycolic acid (diacneal) for mild to moderate acne vulgaris. A
multicentre, double-blind, randomized, vehicle-controlled trial. Dermatology
2005; 210 (Suppl. 1): 14–21.
32. Аравийская Е.Р., Соколовский Е.В., Кирпичева А.А. и др. Место
новых средств для базового ухода, содержащих производные ви-
тамина А и гидроксикислоты, в ведении пациентов с акне. Клин.
дерматол. и венерол. 2006; 1: 53–8.
33. Dreno B, Nocera T, Verriere F et al. Topical retinaldehyde with glycolic
acid: study of tolerance and acceptability in association with antiacne
treatments in 1,709 patients. Dermatology 2005; 210 (Suppl. 1):
22–9.
34. Katsambas AD. RALGA (Diacneal), a retinaldehyde and glycolic acid
association and postinflammatory hyperpigmentation in acne--a
review. Dermatology 2005; 210 (Suppl. 1): 39–45.
35. Boisnic S, Branchet-Gumila MC, Nocera T, Verriere F. RALGA (Diacneal)
decreases melanin content in a human skin model. Dermatology
2005; 210 (Suppl. 1): 35–8.
36. Kasraee B, Tran C, Sorg O, Saurat JH. The depigmenting effect of
RALGA in C57BL/6 mice. Dermatology 2005; 210 (Suppl. 1): 30–4.